The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
102 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,383,542 in first-year total cost, median $135,540.
Most frequent study sections
- Special Emphasis Panel[ZCA1 SRB-2 (M2)]9
- Special Emphasis Panel[ZCA1 RTRB-Z (J1)]6
- Special Emphasis Panel[ZCA1 SRB-A (J1)]5
- Special Emphasis Panel[ZCA1 RTRB-Z (O1)]4
- Special Emphasis Panel[ZCA1 SRB-2 (J2)]4
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR5
- BAYLOR COLLEGE OF MEDICINE3
- BRIGHAM AND WOMEN'S HOSPITAL3
- EMORY UNIVERSITY3
- HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Pilot Studies of NN-01-195, a New Tumor-Targeted AURKA Inhibitor1R03CA292552-01A1 | GOLEMIS, ERICA A.SALVINO, JOSEPH M | RESEARCH INST OF FOX CHASE CAN CTR, PA | $186,000 | ZCA1 |
| 2025 | Evaluating the ELF5 Clock as a Biomarker in Breast Cancer Prevention Trials1R03CA300614-01 | MIYANO, MASARU | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $178,000 | ZCA1 |
| 2025 | Targeting the Undruggable in Castration-Resistant Prostate Cancer with FTDR-Stapled Peptide Probes1R03CA304040-01 | KOLENKO, VLADIMIR MWANG, ROSS | TEMPLE UNIV OF THE COMMONWEALTH, PA | $177,209 | ZCA1 |
| 2025 | Investigation of the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma1R03CA299053-01 | HILLENGASS, JENS | ROSWELL PARK CANCER INSTITUTE CORP, NY | $173,500 | ZCA1 |
| 2025 | HPV and HPV-related cancer prevention prevalence among people experiencing homelessness in the United States, 2006-20181R03CA303738-01 | GALVIN, ANNALYNN MAGUDDAYAO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $170,409 | ZCA1 |
| 2025 | Epigenetic Regulation of Melanoma-Associated Fibroblast Plasticity1R03CA300825-01 | FILIPESCU, DAN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $169,000 | ZCA1 |
| 2025 | Risk Factors and Prediction Modeling for Multiple Recurrences of Non-Muscle Invasive Bladder Cancer1R03CA292965-01A1 | AGALLIU, ILIR | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $168,000 | ZCA1 |
| 2025 | Targeting a novel glyco-immune checkpoint for cancer immunotherapy1R03CA304044-01 | CHIORAZZI, MICHAEL | YALE UNIVERSITY, CT | $167,771 | ZCA1 |
| 2025 | Understanding the communication between cancer cells and cancer-associated fibroblasts in chronic lymphocytic leukemia: roles clarification and therapeutic targets exploration1R03CA293119-01A1 | CHEN, SHIH-SHIH | FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, NY | $167,500 | ZCA1 |
| 2025 | Modulation of the migratory dendritic cell tumor-immune microenvironment as a novel treatment for SMARCA4-mutant lung adenocarcinoma using combined anti-ICAM1 and anti-PD-L1 therapies1R03CA304033-01 | TAYLOR, MATTHEW D | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $166,800 | ZCA1 |
| 2025 | Health Communications for Adults Smoking Nondaily1R03CA286623-01A1 | SHOREY FENNELL, BETHANY | UNIVERSITY OF KENTUCKY, KY | $164,484 | ZCA1 |
| 2025 | Dissecting clonal determinants of platinum/PARP inhibitor cross-resistance in ovarian cancer1R03CA303904-01 | CITRON, FRANCESCA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $164,000 | ZCA1 |
| 2025 | Development of Cancer Care Shortage Areas Using Geospatial Analysis and Spatial Network Optimization Techniques1R03CA304056-01 | WANG, CHANGZHEN | UNIVERSITY OF ALABAMA IN TUSCALOOSA, AL | $163,817 | ZCA1 |
| 2025 | Targeting of E-cadherin-negative diffuse-type gastric cancer1R03CA296049-01A1 | PARK, JAE-IL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $163,500 | ZCA1 |
| 2025 | Targeting the HER Family in KRAS Mutant Colorectal Cancer1R03CA304041-01 | GARRETT, JOAN T. | UNIVERSITY OF CINCINNATI, OH | $162,000 | ZCA1 |
| 2025 | Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles1R03CA292132-01A1 | POVERO, DAVIDE | MAYO CLINIC ROCHESTER, MN | $161,400 | ZCA1 |
| 2025 | Mouse models of caspase-2 deficient nucleophosmin-mutated AML1R03CA303759-01 | BOUCHIER-HAYES, LISA | BAYLOR COLLEGE OF MEDICINE, TX | $160,500 | ZCA1 |
| 2025 | Role of STAT in heterochromatin initiation1R03CA286683-01A1 | LI, WILLIS X | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $159,500 | ZCA1 |
| 2025 | Open IPO and QA platform for conformal FLASH proton therapy1R03CA300834-01 | LIN, LIYONG | EMORY UNIVERSITY, GA | $158,899 | ZCA1 |
| 2025 | TIP60-chromatin remodeling complex roles in chromosome break repair1R03CA304032-01 | BOULEY, RENEEPETREACA, RUBEN CIPRIAN | OHIO STATE UNIVERSITY, OH | $157,500 | ZCA1 |
| 2025 | Integrative Multi-Omics of Metabolomics and Epigenetics to Explore thePathophysiology of Cachexia and Survival in Head and Neck SquamousCell Carcinoma1R03CA304028-01 | ELDRIDGE, RONALD C | EMORY UNIVERSITY, GA | $156,500 | ZCA1 |
| 2025 | A National Cohort Study Examining Breast Cancer Diagnostics, Treatments, and Outcomes in Individuals on Hormone Therapy1R03CA300739-01 | CORTINA, CHANDLER SCOTT | MEDICAL COLLEGE OF WISCONSIN, WI | $156,000 | ZCA1 |
| 2025 | Establishing an in-vivo Sleeping-Beauty Screen to Identify and Characterize Novel Drivers of Melanomagenesis in a Nevi-Prone Zebrafish Model.1R03CA297549-01A1 | KENNY, COLIN P | UNIVERSITY OF IOWA, IA | $155,500 | ZCA1 |
| 2025 | One cell, one cancer: a novel genetic approach to mouse models of human cancer initiation1R03CA305593-01 | MURTAUGH, LEWIS C | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, UT | $154,000 | ZCA1 |
| 2025 | Conditional Agonism: PD1-Dependent Activation of 4-1BB for Enhanced Safety1R03CA300928-01 | SANDEY, MANINDER | AUBURN UNIVERSITY AT AUBURN, AL | $153,959 | ZCA1 |
| 2025 | Developing a Dre-rox Recombination-Based Genetically Engineered Mouse Model (GEMM) for NUT Carcinoma1R03CA299539-01 | GU, BIN | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | $153,278 | ZCA1 |
| 2025 | Optimizing knocksideways to visualize interactions between protein subcomplexes1R03CA303743-01 | LIU, SONG-TAO | UNIVERSITY OF TOLEDO, OH | $153,000 | ZCA1 |
| 2025 | NMR strategies to probe allosteric effects of inhibitor binding on AML-associated Src-family kinases1R03CA293105-01A1 | ISHIMA, RIEKO | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $151,920 | ZCA1 |
| 2025 | Understanding interplay between the Hsp70 chaperone code and Cyclin D1/Cln31R03CA289058-01A1 | TRUMAN, ANDREW WILLIAM | UNIVERSITY OF NORTH CAROLINA CHARLOTTE, NC | $150,784 | ZCA1 |
| 2025 | Evaluate the role of extracellular vesicles in tumor microenvironment modulation1R03CA303913-01 | SOHAL, IKJOT SINGH | UNIVERSITY OF NORTH TEXAS, TX | $148,500 | ZCA1 |
| 2025 | Cancer Outcomes among Michigan Residents Exposed to Polybrominated Biphenyls1R03CA289843-01A1 | MARCUS, MICHELE | EMORY UNIVERSITY, GA | $139,779 | ZCA1 |
| 2025 | Development of a novel dual inhibitor for treatment of MYCN-amplified neuroblastoma1R03CA300831-01 | WEISSMILLER, APRIL M. | MIDDLE TENNESSEE STATE UNIVERSITY, TN | $131,300 | ZCA1 |
| 2025 | Characterization of HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity via Fc Receptor (CD16a) blockade1R03CA302674-01 | GRASSO, LUIGI | NAVROGEN, INC., PA | $115,000 | ZCA1 |
| 2025 | Improving the potency of novel PRMT5 inhibitor with nanocrystal technology to treat pancreatic cancer1R03CA283225-01A1 | LU, TAOYEO, YOON | INDIANA UNIVERSITY INDIANAPOLIS, IN | $89,349 | ZCA1 |
| 2025 | Examining Barriers to Lung Cancer Screening1R03CA297359-01 | WAIN, KRIS | KAISER FOUNDATION RESEARCH INSTITUTE, CA | $83,500 | ZCA1 |
| 2025 | Mixed Lineage Kinase 2 (MLK2) in tumor angiogenesis1R03CA295675-01 | KANT, SHASHI | BRIGHAM AND WOMEN'S HOSPITAL, MA | $83,180 | ZCA1 |
| 2025 | The shared and distinct cistromes of YAP and TAZ in melanoma1R03CA288281-01A1 | LANG, DEBORAH | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $81,750 | ZCA1 |
| 2025 | Development of anti-cancer probes targeting ferroptosis pathway1R03CA289556-01A1 | SKOUTA, RACHID | UNIVERSITY OF MASSACHUSETTS AMHERST, MA | $81,041 | ZCA1 |
| 2025 | Exploring Cumulative Social Determinants Burden, Cancer, and Accelerated Aging: The Role of Physical Activity as a Moderator1R03CA297274-01 | BELLIZZI, KEITH M | UNIVERSITY OF CONNECTICUT STORRS, CT | $80,500 | ZCA1 |
| 2025 | Human stem and progenitor-based models of lung adenocarcinoma1R03CA289845-01A1 | KADUR LAKSHMINARASIM, PREETISH | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $80,165 | ZCA1 |
| 2025 | Biochemical determinants of genome instability induced by eukaryotic topoisomerase II1R03CA297372-01 | NITISS, JOHN L | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $80,165 | ZCA1 |
| 2025 | Unveiling a Novel Mechanism of Oncovirus-Induced Carcinogenesis1R03CA297201-01 | CAO, JIAN | RUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ | $78,500 | ZCA1 |
| 2025 | Racial disparities in breast cancer risk and gene expression-roles of genetics and lifestyle factors1R03CA293127-01A1 | PING, JIE | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $77,353 | ZCA1 |
| 2025 | Silencing B7-H3 mitigates tumor aggressiveness in group 3 medulloblastoma1R03CA297351-01 | MAHAPATRA, SIDHARTH | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $76,750 | ZCA1 |
| 2025 | Feasibility and Adaptation of an Evidence-Based Multilevel Intervention for Improving Timeliness of Lung Cancer Treatment1R03CA297362-01 | NDUAGUBA, SABINA | WEST VIRGINIA UNIVERSITY, WV | $76,000 | ZCA1 |
| 2024 | Informing Lifestyle Recommendations for Kidney Cancer Survival: Investigating the Role of Dietary Patterns and Physical (In)activity1R03CA282955-01A1 | GRAFF, REBECCA ELIZABETHPRESTON, MARK ARTHUR | BRIGHAM AND WOMEN'S HOSPITAL, MA | $189,163 | ZCA1 |
| 2024 | Nonresponse of Patient-reported Outcomes in Routine Cancer Care1R03CA292987-01 | LIU, JASON BZENG, CHENGBO | BRIGHAM AND WOMEN'S HOSPITAL, MA | $179,000 | ZCA1 |
| 2024 | Understanding the pathogenesis of classic Hodgkin lymphoma in persons living with HIV through conventional and spatial transcriptomics1R03CA288191-01A1 | NARESH, KIKKERI | FRED HUTCHINSON CANCER CENTER, WA | $176,000 | ZCA1 |
| 2024 | Gut Microbiome Profiles in Association with Breast Cancer Recurrence and Mortality1R03CA292953-01 | NGUYEN, SANG MINHSHU, XIAO-OU | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $175,000 | ZCA1 |
| 2024 | Impact of Rural Hospital Closures on Cancer Outcomes and Cancer Racial Disparity among Medicare Beneficiaries1R03CA292975-01 | LIU, ZHAOLI | UNIVERSITY OF TEXAS ARLINGTON, TX | $171,163 | ZCA1 |
| 2024 | Develop a PET radiotracer suitable for in vivo imaging of TGFβ1R03CA283104-01A1 | YOUNG, KRISTINA H | PROVIDENCE HEALTH & SERVICES - OREGON, WA | $170,000 | ZCA1 |
| 2024 | Using real-time data capture to examine implicit attitudes as mediators of physical activity adherence in interventions1R03CA292977-01 | DUNTON, GENEVIEVE FRIDLUND | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $166,000 | ZCA1 |
| 2024 | Employing quantitative image analysis based on deep learning to improve treatment efficacy in image-guided renal tumor ablation1R03CA286693-01A1 | BAI, HARRISONKIMIA, BENJAMIN | BROWN UNIVERSITY, RI | $164,639 | ZCA1 |
| 2024 | Novel estrogen receptor mutations as a biomarker dictating therapy response in advanced endocrine-resistant estrogen receptor-positive breast cancer1R03CA293120-01 | NAYAR, UTTHARA | JOHNS HOPKINS UNIVERSITY, MD | $163,750 | ZCA1 |
| 2024 | Role of Grail in colon inflammation and tumorigenesis1R03CA286624-01A1 | NURIEVA, ROZA INSAFETDINOVNA | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $163,500 | ZCA1 |
| 2024 | Tumor stem cell initiated mitochondrial transfer1R03CA293129-01 | CHEN, KUAN-HUI | TEXAS TECH UNIVERSITY, TX | $161,794 | ZCA1 |
| 2024 | Couples' Communication about Sexuality when Facing Metastatic Breast Cancer1R03CA277198-01A1 | DENES, AMANDA | UNIVERSITY OF CONNECTICUT STORRS, CT | $161,000 | ZCA1 |
| 2024 | Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems1R03CA292991-01 | CARROLL, NIKKI | KAISER FOUNDATION RESEARCH INSTITUTE, CA | $158,290 | ZCA1 |
| 2024 | Support for bereaved friend and family caregivers of cancer patients1R03CA282943-01A1 | LEHTO, REBECCA H | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | $157,000 | ZCA1 |
| 2024 | Nurses Surviving Breast Cancer: An exploration of breast cancer diagnosis, reported lymphedema symptoms, and lifestyle status in the Nurses' Health Study Survey1R03CA289066-01 | ANDERSON, ELIZABETH A | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $156,500 | ZCA1 |
| 2024 | Circulating tumor cell profiling for genomic contributors to racial disparity in metastatic prostate cancer1R03CA292985-01 | WANG, CHUN | THOMAS JEFFERSON UNIVERSITY, PA | $156,000 | ZCA1 |
| 2024 | Activation of SLFN12 RNase Activity by Dimerization1R03CA293115-01 | GREULICH, HEIDI | BROAD INSTITUTE, INC., MA | $154,400 | ZCA1 |
| 2024 | Identification of essential biomarkers in the polyploid cancer cell lifecycle1R03CA286532-01A1 | DELANEY, JOE RVOELKEL-JOHNSON, CHRISTINA | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $151,000 | ZCA1 |
| 2024 | A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis1R03CA292128-01 | GUPTA, ROMI | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $148,500 | ZCA1 |
| 2024 | Role of JMJD4 in Pancreatic Cancer1R03CA292973-01 | JANKNECHT, RALF | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $145,000 | ZCA1 |
| 2024 | Structure of the BRCA1-PALB2-BRCA2 complex1R03CA289842-01 | EVANS, JAMES E | BATTELLE PACIFIC NORTHWEST LABORATORIES, WA | $99,459 | ZCA1 |
| 2024 | Deciphering the dichotomy of oxygen metabolism in renal cancer using a novel genetically encoded oxygen biosensor1R03CA286706-01 | CRACAN, VALENTIN | SCINTILLON INSTITUTE FOR PHOTOBIOLOGY, CA | $96,300 | ZCA1 |
| 2024 | Divergent Functions of ERK2 Substrate Binding Domains in Pathogenesis of KRAS-Driven Pancreatic Cancer1R03CA286669-01 | ASTSATUROV, IGORWIEST, DAVID L. | RESEARCH INST OF FOX CHASE CAN CTR, PA | $94,000 | ZCA1 |
| 2024 | A sensitivity analysis framework for generalizing randomized clinical trial results in the presence of unmeasured treatment effect modifiers1R03CA280007-01A1 | ANDRIDGE, REBECCA ROBERTS | OHIO STATE UNIVERSITY, OH | $90,722 | ZCA1 |
| 2024 | PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer1R03CA286680-01A1 | HIGGINSON, DANIEL | SLOAN-KETTERING INST CAN RESEARCH, NY | $88,000 | ZCA1 |
| 2024 | Linking lifestyles with tumor immune profiles to identify strategies for improving breast cancer outcomes1R03CA289559-01 | CANNIOTO, RIKKI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $86,750 | ZCA1 |
| 2024 | Targeting BRCA1/2-deficient cancers with folate and vitamin C1R03CA289863-01 | BLENIS, JOHNBURGOS-BARRAGAN, GUILLERMO | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $84,750 | ZCA1 |
| 2024 | The role of UbcH7 in male breast cancer1R03CA289857-01 | KUROKAWA, MANABU | KENT STATE UNIVERSITY, OH | $84,433 | ZCA1 |
| 2024 | Targeting ULK3 for the treatment of triple negative breast cancer1R03CA286682-01 | TAURO, MARILENA | H. LEE MOFFITT CANCER CTR & RES INST, FL | $84,250 | ZCA1 |
| 2024 | Investigating lipid phenotype as a metabolic adaptation to microenvironmental stress1R03CA280404-01A1 | PILLAI, SMITHA R | H. LEE MOFFITT CANCER CTR & RES INST, FL | $84,250 | ZCA1 |
| 2024 | Mini-gantry for proton therapy1R03CA280213-01A1 | CLASIE, BENJAMIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $83,500 | ZCA1 |
| 2024 | Circulating tumor DNA guided de-escalation of frontline diffuse large B-cell lymphoma therapy1R03CA286676-01 | CHERNG, HUA-JAY JEFFERY | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $82,250 | ZCA1 |
| 2024 | Calcium metabolism and lung cancer preneoplasia1R03CA279867-01A1 | PARK, JAE-IL | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $81,000 | ZCA1 |
| 2024 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor1R03CA289563-01 | ZOU, JUN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $81,000 | ZCA1 |
| 2024 | Refinement of a Training Module to Improve Discussions of Sexual Orientation and Gender Identity in Cancer Clinics1R03CA289560-01 | CATHCART-RAKE, ELIZABETH | MAYO CLINIC ROCHESTER, MN | $80,700 | ZCA1 |
| 2024 | c-Myc regulation by TGF-beta signaling as a therapeutic target in Osteosarcoma1R03CA273468-01A1 | CHOI, SUNG HEE | CASE WESTERN RESERVE UNIVERSITY, OH | $80,500 | ZCA1 |
| 2024 | Heterogeneous Genetic Architecture in Lung Cancer Risk1R03CA277197-01A1 | BYUN, JINYOUNG | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2024 | Identifying germline pathogenic variants in familial lung cancer among African-Americans1R03CA282953-01A1 | LIU, YANHONG | BAYLOR COLLEGE OF MEDICINE, TX | $80,000 | ZCA1 |
| 2024 | Using Qualitative Methods to Capture Experiences of Breast Cancer Patients and Characterize Knowledge Types and Levels: The First Step in Informing Patient Knowledge Sharing1R03CA283228-01A1 | PAPAUTSKY, ELIZABETH LERNER | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $79,950 | ZCA1 |
| 2024 | Combined targeting of synthetic lethal partners in RB1-deficient cells1R03CA286521-01 | PARKHITKO, ANDREY A | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $79,500 | ZCA1 |
| 2024 | Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia1R03CA286694-01 | BRAMMER, JONATHAN EDWARD | OHIO STATE UNIVERSITY, OH | $78,750 | ZCA1 |
| 2024 | Human brain organoids as a novel platform for evaluating effects of radiation in the CNS and screening for radiation mitigators1R03CA289852-01 | HE, LING | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $78,666 | ZCA1 |
| 2024 | Developing humanized Nut Carcinoma mouse model for developing NUTM1 targeted therapies.1R03CA286646-01 | GU, BIN | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | $78,500 | ZCA1 |
| 2024 | Genetically engineered mouse models to investigate the liposarcoma microenvironment1R03CA280126-01A1 | ANGELES, CHRISTINA VADALA | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $78,000 | ZCA1 |
| 2024 | Enhancing intratumoral T cell infiltration by deliver of shCXCL5 in a Plectin targeted AAV to improve checkpoint blockade efficacy1R03CA286703-01 | VANSAUN, MICHAEL NATHAN | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $77,500 | ZCA1 |
| 2024 | Elucidating molecular mechanisms of cabozantinib resistance in liver cancer1R03CA289838-01 | QIU, WEI | LOYOLA UNIVERSITY CHICAGO, IL | $77,000 | ZCA1 |
| 2024 | Regulation of esophageal tumorigenesis by protein adduction1R03CA286671-01 | CASPA GOKULAN, RAVINDRAN | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $76,750 | ZCA1 |
| 2024 | Development of immunocompetent melanoma brain metastases organoids1R03CA289645-01 | RODRIGUEZ, ANALIZ | UNIV OF ARKANSAS FOR MED SCIS, AR | $76,500 | ZCA1 |
| 2024 | "SMART" nanoparticle delivery of veratridine overcomes clinical challenges in metastatic colorectal cancer.1R03CA290549-01 | REZVANI, KHOSROW SAMUEL | UNIVERSITY OF SOUTH DAKOTA, SD | $74,750 | ZCA1 |
| 2024 | Anti-cancer effects of tocotrienols and a carboxychromanol in an innovative colon cancer model1R03CA283236-01A1 | JIANG, QING | PURDUE UNIVERSITY, IN | $74,517 | ZCA1 |
| 2024 | Uncoupling Ral signal transduction from Exocyst functions1R03CA289854-01 | REINER, DAVID | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TX | $73,476 | ZCA1 |
| 2024 | Covalent PD1 Antagonists: Discovery of Protein-Protein Interaction (PPI) Inhibitors in Cancer Immunotherapy1R03CA286528-01 | ROCHE, STEPHANE P | FLORIDA ATLANTIC UNIVERSITY, FL | $73,221 | ZCA1 |
| 2024 | Role of JMJD4 in Breast Cancer1R03CA289562-01 | JANKNECHT, RALF | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $72,500 | ZCA1 |
| 2024 | Novel TCR transgenic mice to study tumor neoantigen-specific T cell responses1R03CA286594-01 | KANE, LAWRENCE P. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $66,992 | ZCA1 |
| 2024 | Discovery of SATB2 Inhibitors for Pancreatic Cancer1R03CA286643-01 | SRIVASTAVA, RAKESH K. | GLAX, LLC, DE | $55,000 | ZCA1 |
| 2024 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer1R03CA286634-01 | ZHANG, JIANMIN | ROSWELL PARK CANCER INSTITUTE CORP, NY | $37,548 | ZCA1 |
| 2024 | Targeting Oxidized PTP1B for Anticancer Drug Discovery1R03CA289646-01 | CARROLL, KATE SUZANNE | UNIVERSITY OF FLORIDA, FL | $37,297 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.